Get started
Author

Irene Aires‐Mejía

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
2015 · B Paiva, A Azpilikueta, et al. · Leukemia · 192
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
2013 · Bruno Paiva, Teresa Paino, et al. · Blood · 185
PDF
The cellular origin and malignant transformation of Waldenström macroglobulinemia
2015 · Bruno Paiva, Luis A. Corchete, et al. · Blood · 110
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
2014 · T Paíno, B Paiva, et al. · Leukemia · 81
Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment
2019 · Noemi Puig, Maria-Victoria Mateos, et al. · Blood · 23
Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity
2019 · Tamara Jiménez‐Solas, Félix López‐Cadenas, et al. · British Journal of Haematology · 19
PDF
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial
2024 · Noemí Puig, Cristina Agulló, et al. · Haematologica · 13
PDF
Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient
2023 · María García-Álvarez, Ana Yeguas, et al. · Biomedicines · 6
PDF
The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)
2019 · Sara Rodríguez, Noemi Puig, et al. · Blood · 2
Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment
2019 · Noemi Puig, Teresa Contreras, et al. · Blood · 1
PD-1 and PD-L1 Are Overexpressed in the "Intermediate CD14+CD16+" and "Non Classical CD14lowCD16+" but Not in the "Classical CD14+CD16-" Monocytes in the Peripheral Blood of Chronic Myelomonocytic Leukemia
2015 · Hae Tha Mya, Maria Diez Campelo, et al. · Blood · 1
Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
2023 · Noemi Puig, Cristina Agullo, et al. · Blood
PDF
Ps1352 Dissecting the Bone Marrow Immune Microenvironment in the Complete Spectrum of Monoclonal Gammopathies: Potential Implications in Disease Pathogenesis
2019 · N. Puig, T. Paíno, et al. · HemaSphere
Pf609 Heavy&light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the Gem‐cesar Trial: Comparison With Conventional and Minimal Residual Disease Imwg Response Assessment
2019 · N. Puig, T. Contreras, et al. · HemaSphere
Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs)
2013 · Bruno Paiva, Luis A Corchete, et al. · Blood
Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS
2013 · Bruno Paiva, Luis A Corchete, et al. · Blood
Phenotypic Identification Of Subclones In Multiple Myeloma With Different Genomic Profile, Clonogenic Potential and Drug Sensitivity
2013 · Teresa Paíno, Bruno Paiva, et al. · Blood
Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL)
2013 · Bruno Paiva, Luis A Corchete, et al. · Blood
Works count: 18
Citation count: 633
H-index: 7
I10-index: 7
Year
Topic
Type